Abstract
In vivo production and systemic delivery of therapeutic antibodies by engineered cells might advantageously replace injection of purified antibodies for treating a variety of life-threatening diseases, including cancer, acquired immunodeficiency syndrome, and autoimmune diseases. We report here that skin fibroblasts retrovirally transduced to express immunoglobulin genes can be used for sustained long-term systemic delivery of cloned antibodies in immunocompetent mice. Importantly, no anti- idiotypic response against the ectopically expressed model antibody used in this study was observed. This supports the notion that skin fibroblasts can potentially be used in antibody-based gene/cell therapy protocols without inducing any adverse immune response in treated individuals.
| Original language | English |
|---|---|
| Journal | Journal of Investigative Dermatology |
| Volume | 115 |
| Issue number | 4 |
| Pages (from-to) | 740-5 |
| Number of pages | 5 |
| ISSN | 0022-202X |
| DOIs | |
| Publication status | Published - 2000 |
